Dr. Jun Ma: On the immunotherapeutic progress and future trends for acute lymphoblastic leukemia based on the studies at EHA 2023

Dr. Jun Ma: On the immunotherapeutic progress and future trends for acute lymphoblastic leukemia based on the studies at EHA 2023

2024.01.16
The 28th European Hematology Association (EHA) meeting was held in Frankfurt, Germany from June 8 to June 11, 2023, adopting a hybrid online and offline conference format. As the largest international conference in the European hematology field, the EHA meeting shares topics in various scientific, clinical, and fundamental researches, covering both benign and malignant hematology and discussing the latest advances in hematology. In the treatment of acute lymphoblastic leukemia (ALL), there was significant progress made at this EHA meeting, mainly focused on immunotherapy. To further grasp the content in this area, Oncology Frontier interviewed Professor Ma Jun from the Harbin Institute of Hematology & Oncology and discussed this topic in detail.
Interview with Dr. Andreas Rimner: The Role of Radiotherapy in the Treatment of Stage III Thymoma

Interview with Dr. Andreas Rimner: The Role of Radiotherapy in the Treatment of Stage III Thymoma

2024.01.15
Thymoma is one of the most common primary tumors in the anterior mediastinum, representing a group of diseases originating from different thymic epithelial cells, characterized by unique clinical and pathological features, often accompanied by various paraneoplastic syndromes. During the "Multidisciplinary Oncology Committee" session held at the 2023 European Lung Cancer Congress (ELCC), several experts discussed the treatment strategies for Stage III thymoma based on a case study. Dr. Andreas Rimner from Memorial Sloan Kettering Cancer Center presented on "The Timing of Radiotherapy in the Treatment of Stage III Thymoma." In an interview with Oncology Frontier, Andreas Rimner shares insights into the role of radiotherapy in the treatment of Stage III thymoma.
Incorporating Cytarabine in Pre-treatment for Haploidentical Stem Cell Transplantation in Extramedullary Acute Leukemia: Safety and Efficacy

Incorporating Cytarabine in Pre-treatment for Haploidentical Stem Cell Transplantation in Extramedullary Acute Leukemia: Safety and Efficacy

2024.01.15
Allogeneic hematopoietic stem cell transplantation is among the most effective methods for treating malignant hematopoietic tumors. However, for extramedullary leukemia, even with high-intensity chemotherapy and transplantation, the recurrence rate remains high. To improve the prognosis, it's essential to optimize the pre-treatment plan and reduce recurrence.At this EBMT annual meeting,Dr. Min Xiong from Hebei Yanda Ludaopei Hospital reported a clinical study (Abstract No.: 1100). Results indicate that a pre-treatment regimen incorporating cytarabine for haploidentical hematopoietic stem cell transplantation to treat extramedullary leukemia is both safe and effective. We've invited Dr. Xiong  for a  interpretation of this research. This retrospective analysis was conducted on 36 patients with extramedullary leukemia who underwent haploidentical allogeneic hematopoietic stem cell transplantation at Beijing Ludaopei Hospital from August 2019 to March 2022. The pre-treatment regimen used BU/CY in 14 cases (38.9%) and TBI/CY in 22 cases (61.1%), combined with cytarabine (5 mg/kg, on days -3 and -2). The overall survival (OS), disease-free survival (DFS), and transplant-related mortality (TRM) of the patients were assessed.
Dr.  Hui Wang: Unlocking a New Approach to MRD Testing in Acute Myeloid Leukemia

Dr.  Hui Wang: Unlocking a New Approach to MRD Testing in Acute Myeloid Leukemia

2024.01.15
The 49th European Bone Marrow Transplantation Annual Meeting (EBMT 2023) took place in Paris, France, from April 23 to 26, 2023. Experts and scholars from various countries gathered to present exciting advancements in research. In the field of blood tests, the fifty-year anniversary of flow cytometry coincided with this year's conference. Over the past half-century, this technology has become an indispensable tool in the diagnosis and follow-up of hematological malignancies. Acute Myeloid Leukemia (AML) is the most common acute leukemia in adults, and the detection of Minimal Residual Disease (MRD) plays a crucial role in clinical treatment and prognosis assessment, despite encountering various technical challenges. With the release of two significant expert consensus statements by the European Leukemia Network (ELN) in 2018 and 2021, technical issues related to AML MRD detection by Multiparameter Flow Cytometry (MFC) were discussed, making this research once again the focus of the hematology field.
Dr. Xingyu Cao: Post-transplant maintenance therapy with Chidamide in T-ALL patients is expected to reduce relapse and improve survival  

Dr. Xingyu Cao: Post-transplant maintenance therapy with Chidamide in T-ALL patients is expected to reduce relapse and improve survival  

2024.01.15
Acute T-cell lymphoblastic leukemia (T-ALL) is a highly heterogeneous malignant tumor of the hematopoietic system caused by the malignant transformation of T-cell precursors. It has significant differences from B-cell precursor acute lymphoblastic leukemia (BCP-ALL) in clinical features, cellular genetics, molecular biology, and abnormal signal transduction pathways. T-ALL accounts for 10%-15% in children and 20%-25% in adults. Adult T-ALL has a poor prognosis due to primary chemotherapy resistance and early recurrence, with a 5-year event-free survival rate of only 20%-50%. The main challenge for T-ALL patients after transplantation is recurrence. From April 23-26, 2023, the EBMT Annual Meeting was grandly held in Paris, France. At the meeting, Dr. Cao Xingyu from Hebei Yanda Ludao Pei Hospital reported a clinical study (abstract number: 351), which suggested that the use of Chidamide for maintenance treatment might improve the survival of T-ALL patients after allogeneic hematopoietic stem cell transplantation (Allo-HSCT).
How to choose the maintenance treatment plan after HSCT for R/R malignant hematological patients?

How to choose the maintenance treatment plan after HSCT for R/R malignant hematological patients?

2024.01.15
Relapse/refractory (R/R) has always been a difficult point in the clinical treatment of malignant hematological tumors. Hematopoietic stem cell transplantation (HSCT) is an important treatment for these patients to achieve long-term survival. Subsequent maintenance treatment is essential to consolidate the effects of HSCT and prevent disease recurrence. Therefore, researchers have been focusing on optimizing the specific maintenance treatment plan for a long time. The 49th annual meeting of the European Blood and Marrow Transplantation Society (EBMT) will be held in Paris, France from April 23rd to 26th. A study from the Beijing Gaobo Medical (Hematology) Research Center, Beijing Gaobo Bo Ren Hospital by Dr. Tong Wu and her team, specifically focuses on the selection of maintenance treatment plans for R/R malignant hematological patients after allogeneic hematopoietic stem cell transplantation. Dr. Zhihui Li shared her comment of this study.